Antisense oligonucleotide drugs are showing renewed promise in neurology, particularly through exon-skipping strategies for Duchenne muscular dystrophy.
Authors
No takes yet. Share an insight, caveat, or question.
Exon-skipping ASOs show promise in DMD; leaves open cardiac efficacy and safety in dedicated trials.
Yokota et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: